Theravance Biopharma (TBPH) Misses Q4 EPS by 7c

Theravance Biopharma (NASDAQ: TBPH) reported Q4 EPS of ($0.43), $0.07 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $14.9 million versus the consensus estimate of $13.77 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• Are we witnessing a fundamental or speculative rally in the S&P 500?
• PVH Corp. (PVH) Tops Q1 EPS by 19c, Offers Guidance
• Fairfax prices $750 million senior notes offering at 6.200% interest